Skip to main content
SpringerLink
Log in
Book cover

Multiple Sclerosis pp 1–15Cite as

Recent Advances and Future Challenges in Multiple Sclerosis Clinical Trial Design

  • Chapter

Abstract

Tore Broman lay down the desiderata for multiple sclerosis (MS) therapeutics in 1970 (Broman 1970):

  1. 1.

    Complete cure of the patient;

  2. 2.

    Success in preventing further relapses;

  3. 3.

    Success in preventing further progress;

  4. 4.

    An acceptable risk that the treatment will be less harmful than the disease.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Albert PS, McFarland HF, Smith ME et al. (1994) Time series for modelling counts from a relapsing-remitting disease: applications to modelling disease activity in multiple sclerosis. Stat Med 13: 453–466

    Article  PubMed  CAS  Google Scholar 

  • Arnold DL, Matthews PM, Francis GS et al. (1992) Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques. Ann Neurol 31 (Suppl 3): 235–241

    Article  PubMed  CAS  Google Scholar 

  • Barkhof F, Hommes OR, Scheltens P, Valk J (1991) Quantitative MRI changes in gadolinium-DTPA enhancement after high-dose intravenous methylprednisolose in multiple sclerosis. Neurology 41: 1219–1222

    PubMed  CAS  Google Scholar 

  • Barkhof F, Frequin ST, Hommes OR et al. (1992) A correlative triad of gadolinium-DTPA MM, EDSS, and CSF-MBP in relapsing multiple sclerosis patients treated with high-dose intravenous methyprednisolone. Neurology 42: 63–67

    PubMed  CAS  Google Scholar 

  • Barkhof F, Tas MW, Frequin ST et al. (1994) Limited duration of the effect of methylprednisolone on changes on MRI in multiple sderosis. Neuroradiology 36: 382–387

    Article  PubMed  CAS  Google Scholar 

  • Bastianello S, Pozzilli D, D’Andrea F et al. (1994) A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year. Can J Neurol Sci 21: 266–270

    PubMed  CAS  Google Scholar 

  • Bergamaschi R, Citterio A, Filippini G et al. (1993) Clinical trials in multiple sclerosis: a critical review. Acta Neurologica (Napoli) 15: 462–474

    CAS  Google Scholar 

  • Bornstein MB, Miller A, Slagle S et al. (1987) A pilot trial of Cop 1 in exacerbating-remitting multiple sderosis. N Engl J Med 317: 408–414

    Article  PubMed  CAS  Google Scholar 

  • Bornstein MS, Miller A, Slagle S et al. (1991) A placebo-controlled, double-blind, randomized, two-center pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology 41: 533–539

    PubMed  CAS  Google Scholar 

  • Broman T (1970) Management of patients with multiple sclerosis. In: Vinken PJ, Bruyn GW (eds) Multiple sclerosis and other demyelinating diseases. North-Holland Publishing Company, Amsterdam, pp 408–425 (Handbook of Clinical Neurology, vol. 9 )

    Google Scholar 

  • Canadian Cooperative Multiple Sclerosis Study Group (1991) The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 337: 441–446

    Google Scholar 

  • Capra R, Marciano N, Vignolo LA et al. (1992) Gadolinium-pentetic acid magnetic resonance imaging in patients with relapsing-remitting multiple sclerosis. Arch Neurol 49: 687–689

    PubMed  CAS  Google Scholar 

  • Devinsky O (1995) Outcome research in neurology: incorporating health-related quality of life. Ann Neurol 37: 141–142

    Article  PubMed  CAS  Google Scholar 

  • Durelli L, Bongioanni MR, Cavallo R et al. (1994) Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MM signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology 44: 406–413

    PubMed  CAS  Google Scholar 

  • Ellison GW, Mickey MR, Myers LW et al. (1980) A pilot study of amantadine treatment of multiple sclerosis. In: Bauer HI, Poser S, Ritter G (eds) Progress in multiple sclerosis research. Springer; Berlin, pp 407–408

    Google Scholar 

  • Ellison GW, Myers LW, Mickey MR et al. (1989) The variable course of multiple sclerosis. Neurology 39 (Suppl 1): 357

    Google Scholar 

  • Ellison GW, Myers LW, Leake BD et al. (1992a) A preliminary trial of gold sodium thiomalate (gst) for multiple sclerosis. Neurology 42 (Suppl 3): 209

    Google Scholar 

  • Ellison GW, Myers LW, Leake BD (1992b) Disability scale influence on rate of worsening of multiple sclerosis patients. Ann Neurol 32: 259A

    Google Scholar 

  • Ellison GW, Myers LW, Leake BD et al. (1994) Design strategies in multiple sclerosis clinical trials. Ann Neurol 36: S108 - S112

    Article  PubMed  Google Scholar 

  • Filippi M, Barker GJ, Horsfield MA et al. (1994a) Benign and secondary progressive multiple sclerosis: a preliminary quantitative MRI study. J Neural 241: 246–251

    Article  CAS  Google Scholar 

  • Filippi M, Horsfield MA, Morrissey SP et al. (1994b) Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 44: 635–641

    PubMed  CAS  Google Scholar 

  • Filippi M, Paty DW, Kappos L et al. (1995) Correlations between changes in disability and T2-weighted brain MM activity in multiple sclerosis: a follow-up study. Neurology 45: 255–260

    PubMed  CAS  Google Scholar 

  • Frank JA, Stone LA, Smith ME et al. (1994) Serial contrast-enhanced magnetic resonance imaging in patients with early relapsing-remitting multiple sclerosis: implications for treatment trials. Ann Neural 36: S86 - S90

    Article  Google Scholar 

  • Goodkin DE, Rudick RA (1989) Exacerbation rates and adherence to disease type in a prospectively followed MS population: implications for clinical trials. Neurology 39: 357

    Google Scholar 

  • Goodkin DE, Ross JS, Medendorp SV et al. (1992) Magnetic resonance imaging lesion enlargement in multiple sclerosis. Disease-related activity, chance occurrence, or measurement artifact? Arch Neurol 49 (Suppl 3): 26l - 263

    Google Scholar 

  • Goodkin DE, Rudick RA, Medendorp SV et al. (1995) Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sderosis. Ann Neurol 37: 30–40

    Article  PubMed  CAS  Google Scholar 

  • Grossman RI (1994) Magnetization transfer in multiple sclerosis. Ann Neurol 36(Suppl):S97–S99

    Article  PubMed  Google Scholar 

  • Gulick EE, Cook SD, Troiano R (1993) Comparison of patient and staff assessment of MS patients health status. Acta Neurol Scand 88: 87–93

    Article  PubMed  CAS  Google Scholar 

  • IFNB Multiple Sclerosis Study Group (1993) Interferon beta-lb is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized double-blind, placebo-controlled trial. Neurology 43: 655–661

    Google Scholar 

  • IFNB Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group (1995) Interferon beta-lb in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 45: 1277–1285

    Google Scholar 

  • Jacobs LD, Cookfair R, Rudick R et al. (1994) Results of a Phase III trial of intramuscular recombinant beta interferon as treatment for multiple sclerosis [abstract). Ann Neurol 36: 259

    Article  Google Scholar 

  • Johnson KP, Brooks BR, Cohen JA et al. (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a Phase III multicenter, double-blind, placebo-controlled trial. Neurology 45: 1268–1276

    PubMed  CAS  Google Scholar 

  • Khoury SJ, Guttmann CR, Orav EJ et al. (1994) Longitudinal MRI in multiple sclerosis: correlation between disability and lesion burden. Neurology 44 (Suppl 11): 2120–2124

    PubMed  CAS  Google Scholar 

  • Kidd D, Thompson AJ, Kendall BE et al. (1994) Benign form of multiple sclerosis: MM evidence for less frequent and less inflammatory disease activity. J Neurol Neurosurg Psychiatry 57 (Suppl 9): 1070–1072

    Article  PubMed  CAS  Google Scholar 

  • Kinnunen E, Timonen T, Pirttila T et al. (1993) Effects of recombinant alpha-2b-interferon therapy in patients with progressive MS. Acta Neurol Scand 87: 457–460

    Article  PubMed  CAS  Google Scholar 

  • Likosky WH, Fireman B, Elmore R et al. (1991) Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study. J Neurol Neurosurg Psychiatry 54: 1055–1060

    Article  PubMed  CAS  Google Scholar 

  • Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. Neurology: in press

    Google Scholar 

  • Mauch E, Kornhuber HH, Krapf H et al. (1992) Treatment of multiple sderosis with mitoxantrone. Eur Arch Psychiatry Clin Neurosci 242: 96–102

    Article  PubMed  CAS  Google Scholar 

  • McDonald WI, Miller DH, Thompson AJ (1994) Are magnetic resonance findings predictive of clinical outcome in therapeutic trials in multiple sclerosis? The dilemma of interferon-beta. Ann Neurol 36: 14–18

    Article  PubMed  CAS  Google Scholar 

  • McFarland HF, Frank JA, Albert PS et al. (1992) Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 32: 758–766

    Article  PubMed  CAS  Google Scholar 

  • Miller DH (1994) Magnetic resonance in monitoring the treatment of multiple sclerosis. Ann Neurol 36: S91 - S94

    Article  PubMed  Google Scholar 

  • Miller DH, Barkhov F, Berry I et al. (1991) Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry 54: 683–688

    Article  PubMed  CAS  Google Scholar 

  • Miller DH, Thompson AJ, Morrissey SP et al. (1992) High dose steroids in acute relapses of multiple sclerosis: MM evidence for possible mechanism of therapeutic effect. J Neural Neurosurg Psychiatry 55 (Suppl 6): 450–453

    Article  CAS  Google Scholar 

  • Minderhoud JM, van der Hoeven JH, Prange AJ (1988) Course and prognosis of chronic progressive multiple sclerosis. Results of an epidemiological study. Acta Neurol Scand 781: 10–15

    Google Scholar 

  • Myers LW, Ellison GW, Leake BD (1993) Progressive phase of multiple sclerosis not a useful entry criterion for therapeutic trials. Ann Neurol 34: 312A

    Google Scholar 

  • Myers LW, Ellison GW, Merrill JE et al. (1995) Pentoxifylline not a promising treatment for multiple sclerosis. Neurology 45 (Suppl 4): A419

    Google Scholar 

  • Nauta JJ, Thompson AJ, Barkhof F et al. (1994) Magnetic resonance imaging in monitoring the treatment of multiple sclerosis patients; statistical power of parallel-groups and crossover designs. J Neurol Sci 122: 6–14

    Article  PubMed  CAS  Google Scholar 

  • Noseworthy JH (1994) Clinical scoring methods for multiple sclerosis. Ann Neurol 36:S80–S85

    Article  PubMed  Google Scholar 

  • Noseworthy JH, Hopkins MB, Vandervoort MK et al. (1993) An open-trial evaluation of mitoxantrone in the treatment of progressive MS. Neurology 43: 1401–1406

    PubMed  CAS  Google Scholar 

  • Noseworthy JH, Ebers GC, Vandervoort MK et al. (1994) The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial. Neurology 44: 16–20

    PubMed  CAS  Google Scholar 

  • Nuwer MR, Packwood JW, Myers LW, Ellison GW (1987) Evoked potentials predict the clinical changes in a multiple sclerosis drug study. Neurology 37: 1754–1761

    PubMed  CAS  Google Scholar 

  • Paty DW (1994) The interferon beta-lb clinical trial and its implications for other trials. Ann Neurol 36: S113 - S114

    Article  PubMed  Google Scholar 

  • Paty DW, Li DR (1993) Interferon beta-lb is effective in relapsing-remitting multiple sclerosis: II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43: 662–667

    PubMed  CAS  Google Scholar 

  • Rudick RA, Goodkin DE (eds) (1992) Treatment of multiple sclerosis: trial design, results, and future perspectives. Springer, London

    Google Scholar 

  • Scheinberg L, Feldman J, Ratzker P et al. (1986) Self-assessment of neurological impairments in multiple sclerosis. Neurology 36 (Suppl 1): 284

    Google Scholar 

  • Silberberg DH (ed) (1994) Multiple sclerosis: approaches to management. Ann Neurol 36:S1–S162

    Article  Google Scholar 

  • Sipe JC, Romine JS, Koziol JA et al. (1994) Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 344: 9–13

    Article  PubMed  CAS  Google Scholar 

  • Smith ME, Stone LA, Albert PS et al. (1993) Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine—enhancing magnetic resonance imaging lesions. Ann Neurol 33: 480–489

    Article  PubMed  CAS  Google Scholar 

  • Smith ME, Albert PS, Stone LA et al. (1995) The use of MRI to evaluate individual heterogeneity in treatment response in multiple sclerosis. Neurology 45: A435

    Google Scholar 

  • Solari A, Amato MP, Bergamaschi R et al. (1993) Accuracy of self-assessment of the minimal record of disability in patients with multiple sclerosis. Acta Neurol Scand 87: 43–46

    Article  PubMed  CAS  Google Scholar 

  • Stone LA, Frank JA, Albert PS et al. (1995) The effect of interferon-β on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing—remitting multiple sclerosis. Ann Neurol 37: 611–619

    Article  PubMed  CAS  Google Scholar 

  • Thompson AJ (ed) (1995) Measurement in multiple sclerosis. MS Management 2:3–57

    Google Scholar 

  • Thompson AJ, Miller D, Youl B et al. (1992) Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration. Neurology 42: 60–63

    PubMed  CAS  Google Scholar 

  • Verdier-Taillefer MH, Roullet E, Cesaro P et al. (1994) Validation of self-reported neurological disability in multiple sclerosis. Int J Epidemiol 23: 148–154

    Article  PubMed  CAS  Google Scholar 

  • Vickrey BG, Hays RD, Harooni R et al. (1995) A health-related quality-of-life measure for multiple sclerosis. Qual Life Res 4: 187–206

    Article  PubMed  CAS  Google Scholar 

  • Weiner HL, Dau P, Khatri B et al. (1989) Double-blind study of true versus sham plasma exchange in patients being treated with immunosuppression for acute attacks of multiple sclerosis. Neurology 39: 1143–1149

    PubMed  CAS  Google Scholar 

  • Weiner HL, Mackin GA, Orav EJ et al. (1992) Effect of age on response of chronic progressive multiple sclerosis patients to cyclophosphamide booster therapy. Neurology 42: 465

    Google Scholar 

  • Weiner HL, Mackin GA, Orav EJ et al. (1993) Intermittent cyclophosphamide plus therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 43: 910–918

    PubMed  CAS  Google Scholar 

  • Weinshenker BG, Bass B, Rice GPA et al. (1989) The natural history of multiple sclerosis: a geographically based study: 2. Predictive value of the early clinical course. Brain 112: 1419–1428

    Article  PubMed  Google Scholar 

  • Weinshenker BG, Rice GP, Noseworthy JH (1991) The natural history of multiple sclerosis: a geographically based study: 4. Applications to planning and interpretation of clinical therapeutic trials. Brain 114: 1057–1067

    Article  PubMed  Google Scholar 

  • Whitaker JN, The Advisory Committee on Clinical Trials on New Agents in Multiple Sclerosis of the National Multiple Sclerosis Society (1993) Expanded clinical trials of treatments for multiple sclerosis. Ann Neurol 34: 755–756

    CAS  Google Scholar 

  • Whitaker JN, McFarland HF, Rudge P et al. (1995) Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Multiple Sclerosis 1: 37–47

    PubMed  CAS  Google Scholar 

  • Yudkin PL, Ellison GW, Ghezzi A et al. (1991) Overview of azathioprine treatment in multiple sclerosis. Lancet 338: 1051–1055

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. George W. Ellison
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The UCSF/Mount Zion Multiple Sclerosis Center, University of California at San Francisco, 1600 Divisadero Street, 94115, San Francisco, CA, USA

    Donald E. Goodkin MD

  2. Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, 9500 Euclid Avenue, 44195-5244, Cleveland, OH, USA

    Richard A. Rudick MD

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Springer-Verlag London Limited

About this chapter

Cite this chapter

Ellison, G.W. (1996). Recent Advances and Future Challenges in Multiple Sclerosis Clinical Trial Design. In: Goodkin, D.E., Rudick, R.A. (eds) Multiple Sclerosis. Springer, London. https://doi.org/10.1007/978-1-4471-1271-6_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-1271-6_1

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-85233-033-0

  • Online ISBN: 978-1-4471-1271-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation